Shares of Teligent, Inc. (NASDAQ:TLGT) have been assigned a consensus rating of “Hold” from the seven ratings firms that are presently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $7.33.
TLGT has been the subject of a number of recent research reports. TheStreet downgraded Teligent from a “c-” rating to a “d+” rating in a research report on Wednesday, November 1st. Roth Capital set a $9.00 target price on Teligent and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Deutsche Bank decreased their target price on Teligent from $9.00 to $8.00 and set a “hold” rating for the company in a research report on Monday, August 14th. Canaccord Genuity downgraded Teligent from a “buy” rating to a “hold” rating and decreased their target price for the stock from $9.00 to $5.00 in a research report on Tuesday, November 7th. Finally, Zacks Investment Research raised Teligent from a “strong sell” rating to a “hold” rating in a research report on Friday, October 13th.
Shares of Teligent (NASDAQ TLGT) opened at $3.98 on Friday. The company has a quick ratio of 2.71, a current ratio of 3.28 and a debt-to-equity ratio of 2.23. Teligent has a 52-week low of $2.82 and a 52-week high of $9.54.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Parkwood LLC purchased a new position in shares of Teligent in the second quarter valued at $112,000. UBS Asset Management Americas Inc. purchased a new position in shares of Teligent in the first quarter valued at $170,000. Voya Investment Management LLC grew its position in shares of Teligent by 16.1% in the second quarter. Voya Investment Management LLC now owns 23,342 shares of the company’s stock valued at $214,000 after purchasing an additional 3,234 shares in the last quarter. Renaissance Technologies LLC purchased a new position in shares of Teligent in the first quarter valued at $198,000. Finally, Aperio Group LLC purchased a new position in shares of Teligent in the second quarter valued at $256,000. Institutional investors own 70.82% of the company’s stock.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.